Cannabis consumption methods compared

Methods of consumption and what really sets them apart

All methods of consumption deliver the same active ingredients into the body, but via different routes — and the route determines three things: how quickly the effects set in, how long they last, and how easily they can be controlled. Inhalation, i.e. smoking and vaporising, takes effect within minutes and subsides after two to four hours; this makes it the easiest to dose, as you feel the effects before consuming more. Oral ingestion via edibles takes 30 to 120 minutes and lasts four to eight hours — offering the poorest control, but the longest duration of action.

In between are sublingual oils, which are partially absorbed directly through the oral mucosa and therefore take effect faster than swallowed products. Topical applications on the skin act locally and with virtually no systemic absorption — they do not cause a high and are intended for localized symptoms.

Combustion itself is the greatest avoidable risk factor. At temperatures above 600 °C, tar, carbon monoxide, and polycyclic aromatic hydrocarbons are produced, which have nothing to do with the effects. Vaporising at 180 to 210 °C largely bypasses this step and is therefore the lower-risk form of inhalation — low-risk does not mean risk-free.

• Inhalation: onset in minutes, 2–4 hours, easily controlled
• Oral: 30–120 minutes to onset, 4–8 hours, poorly controlled
• Sublingual: faster onset than swallowed, medium duration
• Topical: local, no psychoactive effect

Low-risk consumption — the Swiss regulatory framework

The most important practical rules are the same regardless of the consumption method: start low and go slow, avoid mixed consumption with alcohol and medication, do not consume under existing psychological distress, and avoid unsafe environments. Mixing cannabis with tobacco introduces additional nicotine addiction and is the reason why many users are far more dependent on tobacco than on cannabis.

Legally, the same threshold applies to all forms: under 1 % total THC is not a narcotic. The decisive factor is always the total THC, i.e. THC plus THCA multiplied by the factor of 0.877. A product with 0.4 % delta-9-THC and 0.9 % THCA has a total THC content of around 1.19 % and is therefore classified as a narcotic — even if the packaging states «under 1 %». For adults, consumption as such of small quantities is an infraction subject to a fixed penalty fine; cultivation, distribution, and trafficking must be clearly distinguished from this.

In road traffic, the detection limit of 1.5 µg/L THC in the blood applies, which is effectively a zero-tolerance policy. In the event of a distressing overdose, rest, a safe place, and fluids help; in case of cardiovascular symptoms or persistent anxiety, Tox Info Suisse can be reached 24/7 at 145.

Orientation within the cluster

The subpages cover the individual methods of consumption, including technique and dosage, the comparison of smoking versus vaporising, bongs and filters, mixed consumption, and how to handle unpleasant experiences.

Anyone looking to reduce the risks of their consumption will find the greatest leverage in the pages on vaporising and mixing with tobacco — both alter the risk profile more significantly than any dosage adjustment.

Swiss pilot trials and regulated sourcing

With the scientific pilot trials in accordance with Article 8b of the Narcotics Act, Switzerland is testing new approaches to handling cannabis. In cities such as Zurich with the Züri Can project or Basel with Weed Care, registered participants receive legal access to quality-tested products. This regulated sourcing differs fundamentally from the unregulated market, as consumers receive precise information about the tetrahydrocannabinol and cannabidiol content. This enables precise dosing and minimizes the risk of consuming contaminated substances or synthetic cannabinoids, representing a milestone for consumer health protection.

Participation in these projects is strictly regulated, limited in time, and linked to scientific surveys. The Federal Office of Public Health closely monitors these trials in order to gain insights for future legislation. For consumers, this means that they operate within a protected framework, but must also fulfill obligations regarding data submission. Furthermore, consumption is usually restricted to private spaces or specific locations. These trials demonstrate how controlled distribution can reduce the risks of consumption through education and standardized products.

• Regulated sourcing via selected points of sale such as pharmacies or social clubs
• Scientific monitoring through regular surveys of participants
• Precise declaration of active ingredient contents for better control of consumption
• Limited validity and strict age limits within the project areas

Cantonal differences in enforcement and fixed penalty fines

Although the Federal Narcotics Act regulates the nationwide framework, the practice of the Swiss cantons shows considerable diversity in enforcement. The possession of up to ten grams of cannabis for personal consumption by adults theoretically leads to a fixed penalty fine of one hundred francs if detected. However, how local police forces handle this offense varies greatly. While some cantons maintain a very liberal practice and often refrain from referral for prosecution in the case of minor quantities, other authorities take consistent action and immediately confiscate the material found.

These cantonal differences create uncertainty for many consumers, as legal certainty fluctuates depending on their location. This can lead to unexpected legal consequences, especially at cantonal borders or during intercantonal commuting. It is therefore advisable to familiarize oneself with the local practices of the respective canton of residence or stay. Furthermore, carrying legal CBD cannabis with a total THC content of less than one percent does not automatically exempt one from police checks, as distinguishing between them on-site is often only possible through rapid tests or laboratory analyses.

• Fixed penalty fine of one hundred francs for minor quantities for adults
• Federalist differences in police control intensity and confiscation
• Risk of confusion between legal CBD and illegal THC cannabis
• No absolutely uniform nationwide handling in everyday public spaces

Medical prescription vs. personal consumption

Since the amendment to the law in August 2022, the medical use of cannabis in Switzerland has been significantly simplified. Doctors can now prescribe corresponding preparations directly and without a time-consuming exceptional authorisation from the Federal Office of Public Health (FOPH). These medical products are subject to the strict quality requirements of Swissmedic and the Pharmacopoeia, which guarantees precise dosing and purity. In contrast to recreational use, the focus here is on therapeutic guidance, where the method of consumption is specifically tailored to the symptoms.

For patients, this legal pathway represents a significant relief and safety in everyday life. Nevertheless, the distinction from recreational use remains essential, as a medical prescription is not a free pass for uncontrolled consumption in public spaces. Health insurance coverage is also not guaranteed and must be clarified on a case-by-case basis. Anyone using cannabis for medical purposes benefits from standardised tinctures, capsules, or flowers obtained through Swiss pharmacies, whose active ingredient profile is precisely documented.

• Direct medical prescription possible without an FOPH exceptional authorisation
• Strict quality controls according to Swissmedic guidelines and pharmacy standards
• Individual therapeutic guidance instead of uncontrolled self-experimentation
• Cost coverage by the compulsory health care insurance only in individual cases

Common errors in dosing and preparation for consumption

A common mistake when consuming cannabis lies in imprecise preparation and an incorrect assessment of the onset dynamics. Especially when vaporising with a vaporizer, many users choose temperatures that are too high, which leads to the unintended release of harmful substances and puts unnecessary strain on the lungs. Incomplete grinding of the plant material also prevents even heating and reduces efficiency. With oral ingestion, on the other hand, a lack of patience often leads to a second dose being taken before the actual onset of action, which can lead to severe overdoses.

Another underestimated aspect is the improper storage of the products. Light, heat, and oxygen degrade the active ingredients contained and convert the active THC into cannabinol over time, which weakens the desired effect and instead has a highly fatiguing effect. Consumers should therefore rely on airtight, dark containers to keep the quality stable. Anyone who neglects these basic principles of consumption hygiene not only increases health risks but also reduces the controllability of the effects and wastes valuable resources.

• Temperatures that are too high during vaporisation lead to the unwanted formation of harmful substances
• Premature redosing of oral products due to an underestimated latency period
• Incorrect storage leads to the degradation of active ingredients and undesirable side effects
• Poor hygiene of consumption devices increases the risk of respiratory infections

FAQ